A retrospective study comparing patterns of care and overall survival (OS) in older patients with metastatic renal cell carcinoma (mRCC) with that of their younger counterparts demonstrated that most concerns regarding clinical trial participation of older patients are unfounded. The findings from this study were published in the Journal of Geriatric Oncology.
Although median age at diagnosis of RCC is 64 years, potential physician concerns regarding organ dysfunction and polypharmacy in older patients with this disease have likely contributed to the underrepresentation of this group of patients in clinical trials.
The purpose of this study was to use real-world demographic and clinical data from the registries of 2 large academic cancer centers to compare treatment patterns and clinical outcomes in older (65 years and older) and younger (younger than 65 years) adult patients with mRCC who had disease progression on first-line therapy or treatment toxicity requiring early discontinuation of first-line therapy. Patients were classified according to their age at initiation of first-line therapy.
Of the 309 patients included in the study, 44.7% were classified as older. Median ages in the 2 groups were 71 years and 56 years. Approximately 70% of patients in both age groups had disease characterized by clear cell histology. Similarly, no significant difference in the distribution of patients according to International Metastatic RCC Database Consortium (IMDC) risk score category was observed when the 2 age groups were compared, with approximately 56% of patients in each group categorized by an intermediate score.